Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 3/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 13/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14670963 | 0.99 | NNMT (0.43) | NNMTSYKMAPK8MAPK9JAK2 | |
| SCHEMBL14671115 | 0.83 | MAPK8 (0.43) | NNMTSYKMAPK8MAPK9 | |
| SCHEMBL14657040 | 0.83 | NNMT (0.41) | NNMTSYKJAK2JAK1JAK3 | |
| SCHEMBL14657467 | 0.82 | NNMT (0.41) | NNMTSYKMAPK8MAPK9JAK2 | |
| SCHEMBL14671014 | 0.79 | MAPK8 (0.44) | NNMTSYKMAPK8MAPK9 | |
| SCHEMBL14657115 | 0.77 | MAPK8 (0.66) | MAPK8MAPK9 | |
| SCHEMBL14657116 | 0.77 | MAPK8 (0.66) | MAPK8MAPK9 | |
| SCHEMBL14657896 | 0.77 | MAPK8 (0.69) | SYKMAPK8MAPK9 | |
| SCHEMBL14657898 | 0.77 | MAPK8 (0.69) | SYKMAPK8MAPK9 | |
| SCHEMBL14658094 | 0.76 | MAPK8 (0.58) | SYKMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | NNMT 480/4885SYK 2460/4885MAPK8 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.